The cost of bempedoic acid ezetimibe, available under the brand name Nexletol and Nexlizet, can vary significantly depending on factors such as insurance coverage, pharmacy, and geographic location. These medications are prescribed to lower LDL cholesterol when used in conjunction with diet and statin therapy.
What is the average out-of-pocket cost for bempedoic acid ezetimibe?
Without insurance, the retail price for a 30-day supply of bempedoic acid ezetimibe can range from approximately $400 to over $600 [1]. For example, a 30-day supply of 180 mg/10 mg tablets can cost around $470 at some pharmacies [2].
Can I get financial assistance or coupons for Nexletol and Nexlizet?
Manufacturer-sponsored savings programs can potentially reduce the out-of-pocket cost for eligible patients. For instance, the Nexletol Savings Card and Nexlizet Savings Card programs may offer as little as a $10 monthly copay for commercially insured patients, with program terms and conditions applying [1][3]. Patients should check the manufacturer's website for current eligibility requirements and savings card details.
How does insurance affect the price of bempedoic acid ezetimibe?
Insurance coverage is a primary determinant of the final cost. Many insurance plans cover bempedoic acid ezetimibe, but the specific copay or coinsurance will depend on the plan's formulary and benefit structure. Patients are advised to contact their insurance provider to understand their coverage details for these medications.
When does the patent for bempedoic acid ezetimibe expire?
The patent landscape for bempedoic acid and its combination with ezetimibe is complex and involves multiple patents. Information regarding patent expiry dates and potential exclusivity periods can be found through resources like DrugPatentWatch.com [4]. Understanding patent timelines is crucial for anticipating the potential introduction of generic alternatives.
What are the alternatives to bempedoic acid ezetimibe?
Besides lifestyle modifications like diet and exercise, other medications are available to manage high LDL cholesterol. These include statins (e.g., atorvastatin, rosuvastatin), ezetimibe alone, PCSK9 inhibitors (e.g., evolocumab, alirocumab), and bile acid sequestrants [5]. The choice of alternative depends on individual patient needs, cholesterol levels, risk factors, and tolerance to different drug classes.